secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010097
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q1 revenue up 26% to $23.4M; net loss widens to $3.5M
--------------------------------------------------------------------

- Net revenue $23.4M (+26% YoY); net loss $3.5M vs $1.8M loss in Q1 2024.
- Adjusted EBITDA improved to $0.7M from $0.3M; gross margin 92% vs 90%.
- Sanara Surgical revenue drove growth; segment net loss $0.6M; Tissue Health Plus loss $2.9M.
- Borrowed $12.25M under amended CRG term loan; $12.25M additional available through Dec 2025.
- Appointed Elizabeth Taylor CFO; exclusive BMI license for OsStic bone void filler and ARC technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000164117225010097/0001641172-25-010097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000164117225010097/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer